Urothelial Cancer | Specialty

Dr Albigès on the Predictive and Prognostic Utility of KIM-1 in High-Risk RCC

July 8th 2024

Laurence Albigès, MD, PhD, discusses the potential predictive and prognostic value of circulating KIM-1 in patients with renal cell carcinoma.

Tazemetostat Plus Pembrolizumab Is Tolerable in Advanced Urothelial Carcinoma

July 8th 2024

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

Erdafitinib Approaches EU Approval for FGFR3+ Unresectable or Metastatic Urothelial Carcinoma

June 28th 2024

The EMA's CHMP has adopted a positive opinion regarding erdafitinib in patients with FGFR3+ unresectable or metastatic urothelial carcinoma.

Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBC

June 27th 2024

Antonio Cigliola, MD, discusses interim efficacy data from the SURE-01 study investigating neoadjuvant sacituzumab govitecan in patients with MIBC.

Sacituzumab Govitecan/Enfortumab Vedotin ± Pembrolizumab Under Investigation in Metastatic Urothelial Carcinoma

June 26th 2024

Bradley McGregor, MD, on the ongoing evaluation of sacituzumab govitecan plus enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.

Perioperative Durvalumab Plus Chemo Meets EFS, OS End Points in MIBC

June 25th 2024

Perioperative durvalumab demonstrated a statistically significant improvement in EFS and OS in muscle-invasive bladder cancer.

Dr Braun on Biopsy Site Selection in Biomarker Testing in ccRCC

June 21st 2024

David Braun, MD, PhD, discusses findings from the molecular analysis of the HCRN GU16-260-Cohort A study.

Dr Maluf on Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer

June 21st 2024

Fernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.

Dr Serzan on the Potential of Botensilimab/Balstilimab to Address Unmet Needs in RCC

June 21st 2024

Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.

Dr Li on Patient Outcomes From the KEYNOTE-057 Trial in BCG-Unresponsive NMIBC

June 20th 2024

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

Dr Bellmunt on Avelumab Maintenance in Advanced Urothelial Carcinoma With Low Tumor Burden

June 18th 2024

Joaquim Bellmunt, MD, PhD discusses findings from a post-hoc analysis for avelumab maintenance in advanced urothelial carcinoma with low tumor burden.

Dr Grivas on Key Updates in Genitourinary Cancer Management

June 17th 2024

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.

Dr Albigès on a Biomarker Analysis of KIM-1 in RCC

June 13th 2024

Laurence Albigès, MD, PhD discusses a biomarker analysis which evaluated the presence of circulating KIM-1 in patients with renal cell carcinoma.

Dr Bellmunt on Predictive Signatures for Checkpoint Inhibitor Responses in Urothelial Cancer

June 11th 2024

Joaquim Bellmunt, MD, PhD, discusses the predictive value of H3K27ac epigenomic and single-cell transcriptional profiling in urothelial cancer.

Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC

June 6th 2024

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab

June 6th 2024

Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.

Dr Bochner on Genetic Heterogeneity in Bladder Cancer

June 5th 2024

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Dr Hernandez-Ilizaliturri on the Implications of the FDA Approval of Liso-Cel for R/R Follicular Lymphoma

June 4th 2024

Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial Cancer

June 4th 2024

Bradley McGregor, MD, discusses the investigation of sacituzumab govitecan plus enfortumab vedotin in metastatic urothelial cancer.

Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma

June 4th 2024

Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.